INS and type 1 diabetes mellitus: The position of these molecules seems to be most significant as they are a subset of commercially employed non-insulin-dependent diabetes mellitus and insulin-sensitizing agents (Figure 1) such as rosiglitazone, epalrestat, ciglitazone, AD-5061, pioglitazone, and so on.